-
Je něco špatně v tomto záznamu ?
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
J. Vackova, I. Polakova, SD. Johari, M. Smahel
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
GAUK 988218
Grantová Agentura, Univerzita Karlova
SVV 260568
Grantová Agentura, Univerzita Karlova
GA19‑00816S
Grantová Agentura České Republiky
LM2018126
Ministerstvo Školství, Mládeže a Tělovýchovy
CZ.02.1.01/0.0/0.0/16_019/0000785
European Regional Development Fund
CZ.1.05/2.1.00/19.0395
European Regional Development Fund
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
33923750
DOI
10.3390/cancers13081935
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Cluster of differentiation (CD) 80 is mainly expressed in immune cells but can also be found in several types of cancer cells. This molecule may either activate or inhibit immune reactions. Here, we determined the immunosuppressive role of CD80 in the tumor microenvironment by CRISPR/Cas9-mediated deactivation of the corresponding gene in the mouse oncogenic TC-1 cell line. The tumor cells with deactivated CD80 (TC-1/dCD80-1) were more immunogenic than parental cells and induced tumors that gained sensitivity to cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockade, as compared with the TC-1 cells. In vivo depletion experiments showed that the deactivation of CD80 switched the pro-tumorigenic effect of macrophages observed in TC-1-induced tumors into an anti-tumorigenic effect in TC-1/dCD80-1 tumors and induced the pro-tumorigenic activity of CD4+ cells. Moreover, the frequency of lymphoid and myeloid cells and the CTLA-4 expression by T helper (Th)17 cells were increased in TC-1/dCD80-1- compared with that in the TC-1-induced tumors. CTLA-4 blockade downregulated the frequencies of most immune cell types and upregulated the frequency of M2 macrophages in the TC-1 tumors, while it increased the frequency of lymphoid cells in TC-1/dCD80-1-induced tumors. Furthermore, the anti-CTLA-4 therapy enhanced the frequency of CD8+ T cells as well as CD4+ T cells, especially for a Th1 subset. Regulatory T cells (Treg) formed the most abundant CD4+ T cell subset in untreated tumors. The anti-CTLA-4 treatment downregulated the frequency of Treg cells with limited immunosuppressive potential in the TC-1 tumors, whereas it enriched this type of Treg cells and decreased the Treg cells with high immunosuppressive potential in TC-1/dCD80-1-induced tumors. The immunosuppressive role of tumor-cell-expressed CD80 should be considered in research into biomarkers for the prediction of cancer patients' sensitivity to immune checkpoint inhibitors and for the development of a tumor-cell-specific CD80 blockade.
Department of Cell Biology Faculty of Science Charles University BIOCEV 252 50 Vestec Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017945
- 003
- CZ-PrNML
- 005
- 20210729104058.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13081935 $2 doi
- 035 __
- $a (PubMed)33923750
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Vackova, Julie $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 245 10
- $a CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade / $c J. Vackova, I. Polakova, SD. Johari, M. Smahel
- 520 9_
- $a Cluster of differentiation (CD) 80 is mainly expressed in immune cells but can also be found in several types of cancer cells. This molecule may either activate or inhibit immune reactions. Here, we determined the immunosuppressive role of CD80 in the tumor microenvironment by CRISPR/Cas9-mediated deactivation of the corresponding gene in the mouse oncogenic TC-1 cell line. The tumor cells with deactivated CD80 (TC-1/dCD80-1) were more immunogenic than parental cells and induced tumors that gained sensitivity to cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockade, as compared with the TC-1 cells. In vivo depletion experiments showed that the deactivation of CD80 switched the pro-tumorigenic effect of macrophages observed in TC-1-induced tumors into an anti-tumorigenic effect in TC-1/dCD80-1 tumors and induced the pro-tumorigenic activity of CD4+ cells. Moreover, the frequency of lymphoid and myeloid cells and the CTLA-4 expression by T helper (Th)17 cells were increased in TC-1/dCD80-1- compared with that in the TC-1-induced tumors. CTLA-4 blockade downregulated the frequencies of most immune cell types and upregulated the frequency of M2 macrophages in the TC-1 tumors, while it increased the frequency of lymphoid cells in TC-1/dCD80-1-induced tumors. Furthermore, the anti-CTLA-4 therapy enhanced the frequency of CD8+ T cells as well as CD4+ T cells, especially for a Th1 subset. Regulatory T cells (Treg) formed the most abundant CD4+ T cell subset in untreated tumors. The anti-CTLA-4 treatment downregulated the frequency of Treg cells with limited immunosuppressive potential in the TC-1 tumors, whereas it enriched this type of Treg cells and decreased the Treg cells with high immunosuppressive potential in TC-1/dCD80-1-induced tumors. The immunosuppressive role of tumor-cell-expressed CD80 should be considered in research into biomarkers for the prediction of cancer patients' sensitivity to immune checkpoint inhibitors and for the development of a tumor-cell-specific CD80 blockade.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Polakova, Ingrid $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Johari, Shweta Dilip $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 700 1_
- $a Smahel, Michal $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 252 50 Vestec, Czech Republic
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 8 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33923750 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104057 $b ABA008
- 999 __
- $a ind $b bmc $g 1676476 $s 1138387
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 8 $e 20210416 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a GAUK 988218 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a SVV 260568 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a GA19‑00816S $p Grantová Agentura České Republiky
- GRA __
- $a LM2018126 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000785 $p European Regional Development Fund
- GRA __
- $a CZ.1.05/2.1.00/19.0395 $p European Regional Development Fund
- LZP __
- $a Pubmed-20210726